biotechnology : Innovation + Job News

So far 10 tech companies have committed to joining the Emerging Technology Center's new Highlandtown office when it makes the move from Canton Oct. 25. 

The city-run tech incubator will relocate to the King Cork and Seal Building, at 101 North Haven St. 

ETC has also signed up two new companies in its virtual-affiliate program, which accounts for about one-third of the 86 companies in its portfolio. Companies in the virtual program do not have offices but can use ETC facilities at the new Highlandtown site or its other office @ JHU Eastern in Charles Village. ETC president Deborah Tillett declined to name the two companies since the paperwork is still in progress. She says she expects the number of clients in the virtual program to grow. 

Tillett said that some of the companies in the ETC Canton are graduating and thus will not be transitioning to the new ETC Highlandtown. The ETC Highlandtown is laid out with dedicated offices for 11 companies, for which 10 offices are already committed. "We filled the offices quickly. We're quite happy," she says.

The Baltimore Development Corp. oversees the ETC, which houses startup and early-stage companies. The new ETC will occupy less square footage in Highlandtown than it did in Canton, though Tillett says the new location has more usable work space.
 
The ETC Highlandtown will occupy 20,000 square feet of the 70,000-square foot King Cork and Seal Building. In Canton, the ETC occupied 45,000 square feet in the Can Company, but only 30,000 square feet was usable for offices. The remaining 15,000 square feet was shared common space.
 
“We paid for it but we could not monetize it,” she says, referring to common space like lobby, halls and stairways. "We need to be thinking efficiency and the Highlandtown building has a more efficient layout and use of square feet."
 
The ETC moved into the Can Company 15 years ago as the neighborhood was transitioning from primarily industrial to a popular residential and retail neighborhood.
 
“Our leaving the space leaves [the Can Company] room for expansion,” she says.
 
Tillett called Highlandtown an “up and coming” neighborhood with “a lot going on.”  It is a state-designated Arts and Entertainment District, near Johns Hopkins Bayview Medical Center, and on the route of the future east-west Red Line light rail.
 
ETC Highlandtown’s 10 tenants are the following: 
• 6^th Street, an online retail marketing program;
• ADASHI Systems, an emergency response management program;
• American Business Forms & Envelopes, which makes software for printed business forms;
• EventRebels, which provides conference and trade show software;
• Foodem, a B2B wholesale food marketer that is hiring;
• NewsUp, an organized news delivery service;
• Pieran Health Technologies, which sells custom health software;
• Same Grain, which develops social discovery technology;
• Adecio, a digital marketing firm; and,
• New Sapience, a language comprehension software maker.
 
Source: Deborah Tillett, Emerging Technology Centers
Writer: Barbara Pash
 
 
 
 
 
 
 
 
 
 

Baltimore biotech firm Ocular Proteomics LLC is seeking its first round of financing within the next six months, for $3 million to $4 million in venture capital. While a closing date for the round has not been determined, the decision follows a $1.2 million federal grant the biotechnology startup recently won to begin clinical trials on macular degeneration diagnosis and treatment. The startup last month moved from Towson to UMB BioPark for larger laboratory facilities.

The venture capital financing will be used for clinical trials, marketing and new hires, according to director of business development Joshua Hines.

The $1.2 million grant comes from the National Eye Institute and National Institutes of Health, and runs for  two years, from May 2013 to May 2015. Next year, the company will apply to renew the grant and, if successful, would receive $1.5 million per year for up to five years.

The $1.2 million grant enables Ocular to start clinical trials for ophthalmic diagnosis based on the company’s discovery of biochemical markers in the vitreous of the human eye. The trials will be held at three locations -- Baltimore, Chicago and Cleveland – and will involve 200 patients with macular degeneration.

Dr. Bert M. Glaser, Ocular’s chief scientific Institutes of Health officer, founded the company in 2009. Dr. Glaser heads the National Retina Institute, of which Ocular is a spinoff.
 
Age-related macular degeneration is the leading cause of blindness among adults. An estimated 15 million Americans have macular degeneration, of whom 2.5 million have the advanced form that threatens their eyesight. If not treated, the disease inevitably leads to blindness.
 
There is no cure for macular degeneration but there is an injectible medication that stops the progression of the disease in about one-third of the patients on whom it is used. However, a patient must wait six months to a year before knowing if the medication is effective. Based on the biomarkers, the company’s focus is to determine if the patient will respond to the medication before then.
 
The privately-financed Ocular has two full-time employees. It is looking to hire two laboratory technicians within the year, and is also seeking up to three college students who are interested in unpaid internships doing eye research.
 
Source: Joshua Hines, Ocular Proteomics LLC
Writer: Barbara Pash

OptiCul Diagnostics Ltd. this month submitted an application to the U.S. Food and Drug Administration for approval of its first product, a device that tests for bacterial presence and promises to shorten hospital stays. Upon regulatory approval, which is expected this year, the Rockville biomedical startup with ties to Baltimore plans to market the device next year.
 
The startup is also seeking $5 million in funding from angel and venture capital investors this year, says CEO and Co-founder Israel Gannot. His wife Gallya Gannot is president and co-founder. Last year, the company raised $400,000 from angel investors.

The startup has eight full- and part-time employees. It plans to hire an additional eight employees, in engineering, marketing and sales, this year in preparation for selling the device in 2014.

Called an Optidet, the device OptiCul is developing can determine if a patient is carrying bacteria and if so which kind within three minutes. 

“The device helps with diagnosis and allows you to treat patients quicker, resulting in shorter hospital stays,” says Gannot, professor of biomedical engineering at Johns Hopkins University and a professor at Tel Aviv University.
 
The Maryland Department of Business and Economic Development awarded grants totaling $300,000 for research, which OptiCul conducted with the University of Maryland microbiology and chemistry departments.  
 
OptiCul Diagnostics was founded in Israel in 2008 with seed money from the Israeli government. In 2010, it opened its American headquarters and main laboratory to the William E. Hanna Jr. Innovation Center, an incubator in Montgomery County, where it is still located.
 
Gannot says the device, about the size of a small box, is designed to be placed in a hospital laboratory and used multiple times. The samples, about the size of business cards, are disposable. The device is priced at $10,000 and the samples at $3 each.
 
The initial marketing focus will be the I-95 corridor, Boston to Washington, D.C.,  where, by Gannot’s count, there are 2,500 hospitals with laboratory facilities.
 

Source: Israel Gannot, OptiCul Diagnostics Inc.
Writer: Barbara Pash
 
 
 
 
 
 

New York City nonprofit Venture for America, which provides entrepreneurship training for recent college graduates, is adding Baltimore to its roster of cities this year.
 
Venture was founded in 2011 to encourage entrepreneurship through practical experience. It officially launched last year in five cities: Detroit, Cincinnati, New Orleans, Las Vegas and Providence, Rhode Island. This year, Baltimore and Cleveland are on board.

In Baltimore, the following companies could get access to talent through Venture: Baltimore Astrum Solar, Parking Panda, Pixelligent, Reify Health, Riskive, SocialToaster and Vigilant Medical.

The fellows, or recent graduates, are recruited from universities nationally, including the University of Maryland at College Park and Johns Hopkins University and, for 2013, University of Maryland Baltimore County and Loyola University of Maryland.

“We send out fellows to cities across the country that have high quality startups and, perhaps, less access to talent than major metropolitan areas,” says Mike Tarullo, vice president of corporate development. “We look for places graduates might not think of going but have great opportunities.”

Most recruits are just getting their undergraduate degree in a variety of majors while others may have already spent a year or two in the workforce.
 
Tarullo calls the selection process “competitive,” with a written application, grade transcripts and interviews on the telephone and in person with board members in New York City. About 10 to 15 percent of applicants are admitted to the program.
 
“We are looking for a high potential for entrepreneurship,” says Tarullo of the fellows, who commit to spending two years in their assigned company and at a fixed salary of $38,000 per year that the company pays.
 
Last year, Venture placed 40 fellows in the five original cities. This year, it is placing 70 fellows in the seven cities. The number going to each city depends on how many companies participate in the program and the “match” between fellows’ interests and startups’ field.
 
“We are hoping 10 fellows come to Baltimore but it depends on the number of startups that are hiring. We don’t have a limit on the number of fellows at each startup but typically it’s one, maybe two,” Tarullo says.

Tarullo says each city to which Venture sends fellows has a different focus. Baltimore is strong on cybersecurity, biotechnology and education technology, he says. “We’re excited to be coming to Baltimore.”

Tarullo credits the Abell Foundation, which gave more than $100,000, for bringing Venture for America to Baltimore. The Maryland Technology Development Corp. (TEDCO); Betamore, the work space for startups in Federal Hill; and the incubator Emerging Technology Center in Canton are helping Venture connect with the startup community.

 
Source: Mike Tarullo, Venture for America
Writer: Barbara Pash
 
 
 
 
 
 

A University of Maryland research team led by Shiladitya DasSarma last month revealed a type of organism that may survive on Mars and other extreme environments. The discovery is a breakthrough in methods of survival under the cold and dry conditions found in Antarctica -- and Mars.

DasSarma’s research for NASA focuses on Halorubrum lacusprofundi, a microbe that was discovered in Deep Lake, a very salty lake in Antarctica.

“It’s a good model for surviving in conditions like Mars,” he says of the microbe whose adaptations allow it to live in a cold, salty environment that is considered similar to some environments on Mars.

The National Space and Atmospheric Administration is funding the research, which was published in a professional journal, with an ongoing multi-year grant for nearly $500,000.                     

DasSarma says there is so much interest in the question of life on Mars because Mars and Earth are sister planets. Both are within the “habitable zone,” close enough to the Sun to sustain life if liquid water is present.

“Mars is much drier and colder than Earth,” he says, but photographs show seasonal flows of brine, or salty water, down the sides of a crater on Mars. “There are probably pools of brine under the surface of Mars.”

DasSarma says the NASA grant is intended to answer basic biotechnology questions.

“NASA is asking, could any organism survive under Mars’ conditions? What molecular adaptations are necessary for survival? Our research determined that certain organisms can survive,” says DasSarma, a professor at the University of Maryland School of Medicine, in downtown Baltimore. DasSarma is also a research scientist with the university’s Institute of Marine and Environmental Technology at the Inner Harbor.

DasSarma and his team have long studied organisms that grow in unusual environments. “Our specialty is understanding how they are able to survive in very dry and salty conditions,” says DasSarma, the key finding being that they have adaptations that allow them to hold onto water.

DasSarma says the microbe he is studying for NASA won't  be found on Mars necessarily. But if life is one day discovered on Mars, “they will be a salt-loving type of organism,” he says, “possibly something like it.”

DasSarma says his research may lead to the development of novel biotechnological applications for use on Earth.

Source: Shiladitya DasSamra, University of Maryland School of Medicine and Institute of Marine and Environmental Technology
Writer: Barbara Pash
 
 
 
 
 
 

Early-stage medical device company Vasoptic Medical Inc. is conducting tests on a device to detect and prevent a progressively worsening eye condition that leads to blindness.

The tests, being held at the Johns Hopkins Wilmer Eye Institute, are required for federal Food and Drug Administration approval. When done in 2014, the Columbia company will seek FDA clearance to market and sell the device.

CEO and general counsel M. Jason Brooke estimates it will cost $7.5 million to bring the device to market. The federal National Institute of Health last year awarded the team a $225,000 development grant. The company next month will apply for a $1 million to $1.5 million NIH Small Business Innovation grant, which is intended to help speed commercialization of promising technology.
 
Johns Hopkins has a $180,000 multi-year grant from the Wallace H. Coulter Foundation, part of which goes to Vasoptic for commercialization. Vasoptic has received a $75,000 grant from Maryland Technology Development Corp., or TEDCO, for commercialization. It is also one of 33 finalists in the state’s InvestMaryland Challenge, the winners and cash prizes to be announced next month.
 
Brooke says the company is considering an angel financing round this year for $500,000.

“We are starting to get recognition of the value of technology among investors,” he says.
 
Brooke and Chief Technology Officer Abhishek Rege are Vasoptic’s current staff. Depending on grants, the company will hire two to four research engineers this year. The company is located in Howard County incubator, the Maryland Center for Entrepreneurship.
 
The so-far unnamed device is intended for the early detection of diabetic retinopathy, a condition caused by both Type I and Type II diabetes. One in nearly three diabetics, or six-to-eight million people, has some form of diabetic retinopathy. Another eye implant invented by Hopkins scientists and manufactured by a California company recently received FDA approval. 
 
In the US, 25 million people have diabetes, seven million people are undiagnosed diabetics and another 80 million people are pre-diabetic. The condition causes reduced blood flow to the tissue of the retina that leads to severe visual impairment and eventually blindness.
 
Brooke says the recommended treatment is regular eye exams to detect the condition and better management of one’s diabetes to slow its progression.
 
Vasoptic is not the only technology to screen for the condition. But other technologies require an ophthalmologist to analyze the images, says Brooke. Vasoptic’s technology is designed to be used by the primary care physician.
 
Vasoptic’s hand-held device captures anatomical images and physiological information like blood vessel flow that its accompanying software analyzes. The device not only detects the existence of the condition but predicts the risk of the diabetic developing it as well.
 
“It’s not hard for an ophthalmologist to detect the condition in its early stage but half of diabetics don’t receive the recommended eye exams” because of the expense and inconvenience, Brooke says . “Our focus is the primary care facility and keeping the device low cost,” likely under $10,000 each.
 
Rege developed the technology while working at the Johns Hopkins department of biomedical engineering. Hopkins filed patent papers and entered into a licensing agreement with Vasoptic to commercialize the device.
 

Source: M. Jason Brooke, Vasoptic Medical, Inc.
Writer: Barbara Pash
 
 

Baltimore BioWorks Inc., a company that provides on-the-job vocational training, hired its first employee from its minority-focused training and employment program last month.

Located at the University of Maryland BioPark, BioWorks plans to hire a total of 12 people in 2013 to add to its staff of four. The vocational employees get a salary and benefits during the year-long training program for biotechnicians.
 
The company’s training program is intended to be self-sustaining and depends on BioWorks’ sales, says John Powers, vice president of marketing and co-founder with president Louise Dalton. The company manufactures and distributes biomedical products for others and under its own brand. It also offers toxicology testing services. Powers says BioWorks' annual revenue is expected to clip $1 million this year, thanks to two new contracts. 
 
Powers says the company anticipates closing a contract with the University of Maryland Medical System within the next few months to manufacture and distribute latex gloves and other products. Last year, Baltimore Bioworks contracted with the National Institute of Health to manufacture and distribute products, for about $30,000 in sales per month. 
 
Powers says the company has $350,000 in annual revenue as of this month. With both the University of Maryland and National Institute contracts, sales will increase to $80,000 to $100,000 per month.
 
While the company’s training program is open to all qualified candidates, Baltimore BioWorks last year signed an agreement with Baltimore City Community College to write the program’s training material in conjunction with it.
 
“If we follow their format on classroom work, vocational employees will earn BCCC college credit as well as a salary,” says Powers.
 
Powers is in talks with the BioTechnical Institute of Maryland Inc. — a scientific training program for entry-level biotechnicians — for the same arrangement.
 
In the fall, the company leased a 14,000-square foot space at 1100 Wicomico St., for manufacturing and distribution.
 
Powers expects to hear this summer about the company’s application for state certification as a minority business enterprise. If approved as an MBE, Baltimore BioWorks would qualify to bid on state contracts that require a set-aside of up to 25 percent for minority- and women-owned companies.
 
“With MBE status, the potential is to be a $5 million company,” says Powers.
 
Source: John Powers, Baltimore BioWorks Inc.
Writer: Barbara Pash

BioHealth Innovation Inc., a nonprofit that seeks to commercialize technology in the biotech and healthcare fields, could open an accelerator for health information technology startups this year.

Co-located in Rockville and in Baltimore, BioHealth wants the accelerator to serve entrepreneurs and small businesses in central Maryland. Upon board approval, the organization plans to identify a location by the first quarter of this year and have it operational by the fourth quarter.
 
“We are evaluating it. We believe there is a need for one. We know there is interest,” BioHealth President and CEO Richard Bendis says. 
 
Also in the works for 2013 is an angel fund, a for-profit investment fund for high net-worth individuals to invest in early-stage biohealth companies, says Bendis, who is anticipating a first close for the fund by the end of 2013.

"We are bridging the gap between Montgomery County and Baltimore, where most of the biohealth assets reside in Maryland," says Bendis. "We are interested in things that have the potential to be commecially relevant -- not only that it works but you can build a product or business around it."

Bendis defines biohealth broadly. It encompasses traditional therapeutics and pharmaceuticals as well as diagnostics, medical diagnostics, health care services, electronic medical records, mobile health and biohealth cybersecurity.

"We see a convergence between technology and devices and pharmaceuticals and biotechnology. All those companies depend on data statistics and analytics," he says.
 
BioHealth Innovation was founded last year as a private-public partnership with the goal of accelerating the commercialization of technology and science affiliated with the biohealth industry in central Maryland.
 
"We work with scientists and entrepreneurs beyond the technology transfer phase. We get involved once they get past the transfer office in the university," says Bendis.

"We have the expertise that can help them do that [commercialize research]. We have investors on our board. We have a person who started and ran a biotech company. We connect people to the resources they need," he says.

To that end, BioHealth Innovation is initiating a program to provide free proposal and review assistance to small businesses that apply for Small Business Innovation Research (SBIR) grants. The SBIR requires federal agencies to set aside 2-1/2 percent of their research budgets, a total of $2.5 billion annually, for grants to small businesses. The goal is to speed commercialization of early-stage projects.
 
Bendis contends that while Maryland’s reputation in science is exceptional and the state is recognized as a leader in life sciences, it has not been as successful as other states in competing for the SBIR grants. Phase 1 grants run about $100,000 to $150,000; phase 2, $1 million and up.
 
At the National Institutes of Health, according to Bendis, Maryland small businesses submitted the third highest number of applications for its SBIR grants. But the state ranked 34^th in winning phase 1 grants and 36^th in winning phase 2 grants.
 
BioHealth Innovation’s assistance is available to anyone, private or academic, who is eligible to apply for an SBIR grant, with a particular emphasis on the National Institutes of Health grants.

BioHealth also offers what it calls "client agreements," and has already signed up a few bioheath start-ups in Baltimore. Bendis says the goal of the client agreements is "to help them move their business plans forward, to help them get clients and identify investors and local technology talent. They have a business but it is pre-revenue."
 
Source: Richard Bendis, BioHealth Innovation Inc.
Writer: Barbara Pash

Life sciences company Plasmonix will begin selling its first product, QuantArray, early this year. The Baltimore County startup plans to commercialize two other products later in 2013, the QuantaWell 100 and the Quanta NP, and will seek $2 million to $3 million for another round of financing, CEO William Gjust says.

Plasmonix develops support tools to detect cells in medical research and clinical diagnostics by enhancing luminescent and fluorescent signals using metal nanoparticles. QuantArray, its latest product, has various applications in performing assays, a test that analyzes components, and enhances luminescent signals hundred-fold over conventional methods. The technology can be be applied not only in the life sciences, but also apparel, paint and cosmetics. 
 
QuantaWell 100 also enhances signals hundred-fold but in a different format than QuantArray. Quanta NP is a supplementary solution that is used to improve the efficiency and sensitivity of commercially available assays.
 
“It’s a rarefied field. There is no direct competition that we are aware of,” says Gust of Plasmonix’ products. 
 
Gust says potential customers are any company or institution that performs assays, from pharmaceutical and biotechnology companies to academic facilities. Market research showed that the average price for standard assays is $25 per substrate microscope slide. Gust says he has not determined a price for QuantArray but it is likely to be slightly higher than the standard assay.
 
In 2011, Plasmonix received $1.5 million from venture capitalists in its initial round of financing. It has also received $200,000 from the Maryland Biotechnology Center and $100,000 from the Maryland Industrial Partnership, to be used by its academic collaborators.
 
Plasmonix grew out academic research, primarily at the University of Maryland Center for Fluorescence Spectroscopy. The company was formed in 2009. In 2011, it moved into the incubator, bwtech@UMBC Research and Technology Park, where it occupies a 1,500-square-foot office. The company employs four.
 
“We are translating academic research into robust, reproducible commercial techniques,” says Gust.
 
Source: William Gust, Plasmonix
Writer: Barbara Pash

In an effort to find ways to lessen the United States’ dependence on foreign oil, the US Department of Energy Argonne National Laboratory has awarded a $150,000 research grant to Pixelligent Technologies to further develop its technology to make industrial and automotive lubricants more efficient. With the prospect of commercializing a product from the research, the Baltimore nanocrystal additive manufacturer is planning to relocate to a larger facility this year although details were not yet available.

The energy department’s Small Business Innovation Research Grant was awarded less than a month after it signed a two-year, $500,000 Cooperative Research and Development Agreement with the Baltimore company for the Argonne Laboratory to analyze and test its proprietary nanocrystal technology. Pixelligent and Argonne will split the cost of the research project.
 
The Cooperative Research and Development Agreements are intended to speed commercialization of private sector technology. Craig Bandes, president and CEO, says that both grants are helping the company to reach its goal of commercializing a product, possibly a low-friction oil, out of nanocrystal additives this year.
 
Bandes says Pixelligent is one of several different technologies the government is looking at, including companies that use other types of additives and biofuels.
 
“We are not the only technology in the area, but we have attracted a high level of interest from the energy department,” says Bandes.
 
In preliminary testing with Argonne, results indicate that by dispersing nanocrystals into oil, there is a significant reduction in engine and equipment friction. Doing so prolongs the life of both, improves the efficiency of both and reduces fuel consumption.

“It’s not just that the oil is improved and gas mileage goes up,” says Bandes, “the department of energy is looking for next generation technology.”

Pixelligent was founded in 2000 in the College Park area. The company moved to an 11,000-square foot building in Baltimore in 2011 that allowed it to develop laboratory and manufacturing facilities. The company manufactures specific nanocrystal additives and polymer nanocomposites for the electronics, semiconductor and industrial markets.
 
Bandes expects to grow the current staff of 26 to 40 to 50 staffers this year. He is currently recruiting for five positions in manufacturing, engineering and business development.
 
Besides the energy department funding, Pixelligent has received $12 million from the US Department of Commerce and the National Science Foundation, and $8.5 million in angel investments.
 
 
Source: Craig Bandes, Pixelligent Technologies
Writer: Barbara Pash

InstantLabs Medical Diagnostics Corp. is entering the animal health/veterinary medicine field next year, with plans to develop a variety of tests for the detection and diagnosis of dangerous pathogens in animals.
 
CEO Steven Guterman says the tests will be based on its general purpose molecular diagnostic test kits, which can be refined for different markets. Located at the University of Maryland BioPark, InstantLabs commercialized its first test kit this year for the food safety market and currently is developing a test kit for the human health/hospital market.
 
“Our goal is to change the way people do food testing," Guterman says. "We spent a lot of time building a device with the power of molecular testing that is small, affordable and easy to use.”
 
Food companies typically send samples to an outside laboratory for testing, a process that can take three to five days for results. InstantLab’s test, for both extraction and identification, can be done on-site, with test results within 12 to 24 hours.
 
Customers include poultry processors, fish farmers and nutritional companies that use the kits to detect different and dangerous bacteria like salmonella, listeria and e-coli.
 
The food safety kits were first sold commercially in spring of 2012. So far, more than a dozen have been sold, half in the US and half overseas. By early 2013, the company will also have a test for the bacteria Vibrio.
 
In human health/hospitals, InstantLab is developing a test kit for MSRA, an antibiotic-resistant staphylococcus infection. It received a $100,000 award from the Maryland Industrial Partnerships to develop a test kit for the detection of MSRA.
 
The company is working with Jennifer Johnson, an assistant professor at the University of Maryland School of Medicine, on the test. It should be ready by the end of 2013, after which the company will begin human trials and seek US Food and Drug Administration approval.
 
InstantLabs was formed in 2008. In 2010, it moved to the University of Maryland BioPark in order to grow internally and have its own laboratory. In 2011, it moved to a larger space in the BioPark, doubling the size of its office.
 
The company has five employees in Maryland. Guterman says it is looking to hire a senior molecular biologist in 2013 for its entry into the veterinary field.
 
Source: Steven Guterman, InstantLabs Medical Diagnostics Corp.
Writer: Barbara Pash

Frederick biotech firm Meridian Biogroup has completed a four-year project for Baltimore contract research and manufacturing firm Paragon Bioservices so its laboratory equipment and programs meet US Food and Drug Administration regulations.

“Our projects are not like construction projects with a definite end. Some are long-term,” says Thomas Blake, Meridian’s Principal and Co-Founder with Alison Demarest.
 
Meridian offers validation and compliance services for biotechnology and pharmaceutical companies. These include testing facilities’ utility systems, developing higher-quality programs and providing extra staff for specific tasks.
 
Meridian’s 37 clients range from large companies like Human Genome Sciences and Osiris Therapeutic to small- and mid-range companies like Paragon Bioservices and startups that want to launch a product and need to comply with FDA regulations. Paragon moved to the University of Maryland, Baltimore BioPark in 2008.
 
Blake says that for MedImmune, another client, Meridian is engaged in more than 30 new and ongoing projects at the company’s sites in Frederick and Gaithersburg in Maryland, and in Pennsylvania and Liverpool, England. Projects for MedImmune include quality assurance, regulatory affairs and FDA inspection.
 
Meridian, a privately held company, has been located at the Frederick Innovation Technology Center since its founding in 2007. It has grown from the two co-founders to a staff of 26.
 
The company was the recipient of the 2012 Incubator of the Year Award in the technology services company category. The Maryland Technology Development Corp. (TEDCO) and the Maryland Department of Business and Economic Development sponsor the annual award.
 
Last spring, the Board of County Commissioners of Frederick County officially recognized the company for its contributions to a variety of charitable and community causes, among them Believe in Tomorrow, Frederick Head Start, Smile Train, Hope Alive and the Frederick Community Action Agency.
 
“We feel it’s important to give back,” says Blake. “Frederick county and city have supported our efforts since we started. We’re pleased to be recognized.”
 
Source: Thomas Blake, Meridian Biogroup
Writer: Barbara Pash

Fyodor Biotechnology Inc. expects to complete human trials on its product to detect malaria next year, with commercial production to begin in 2014. The Baltimore biotech firm is also in the planning stages for a second product, a variation of the first, that should be ready for production by 2015. The tests are significant for diagnosis and treatment of an illness that is endemic in developing countries around the world. 

"The tests will be revolutionary in malaria circles," says Eddy Agbo, CEO and chairman of the board of Fyodor, which has established a global network of malaria health professionals.

Fyodor Biotechnology is working with partners who will manufacture and distribute the tests, which will be sold to government and non-government organizations like the World Health Organization, travelers and the military. The tests are for citizens and visitors to countries in the "frontier" market, aka developing countries.

The University of Maryland School of Medicine is conducting the human trials on the first product in Nigeria and Mali. The Urine Malaria Test is the first urine-based test geared to the type of malaria seen in Africa, the Caribbean and South America. The second product will detect the malaria strain found in Asia, China and India. It, too, is the first urine-based test for this malarial type and human trials will also be conducted.  
 
The human trials are required to obtain approval from the US. Food and Drug Administration. While FDA approval is not necessary to sell the products in other countries, it validates them, Agbo says. 
 
Agbo says the tests resulted from Johns Hopkins University’s global health initiative. Using technology that came out of the initiative, Fyodor created a one-step test that is accurate, easy to use, and quick. Test results are available within 20 minutes.
 
Founded in 2008, Fyodor was initially housed in the University of Maryland BioInnovation Center. It subsequently moved to the University of Maryland BioPark where, in July, it relocated from a 700-square foot space to a 2,000-square foot space.
 
The company is doubling its staff, from its current three full-time employees to hiring another three full-time employees by 2013 with expertise in chemistry and recumbent DNA technology. It is also looking for several part-time employees and interns who are familiar with biology, chemistry and laboratory procedures.
 
So far, Fyodor has attracted a total of $2 million in state and federal grants and from private investors, including Maryland Technology Development Corp. and the National Science Foundation (NSF). In August, NSF awarded the company a grant of $476,000 to continue its research.
 
Source: Eddy Agbo, Fyodor Biotechnology
Writer: Barbara Pash

Johns Hopkins University Applied Physics Laboratory researchers are talking with entrepreneurs about commercializing a revolutionary prosthetic limb that can be operated by a person's thoughts. 

The limb uses different mechanisms for brain control, including a brain/computer interface for spinal cord patients and surface electrodes for amputees. Researchers at APL and its five partners are essentially taking technology developed for the prosthetic limb and applying it to both spinal cord patients and to amputees. 
 
Michael McLoughlin, deputy business area executive for research and exploratory development at Laurel's APL declined to provide more information about the commercialization prospects, saying that “nothing has been signed.”  McLoughlin says that preparations are underway to demonstrate the brain/computer interface on human subjects, a first as far as he knows. Plans call for working with five patients with spinal cord injuries.

“Spinal cord patients have a break in the nerves that go from the arm to the brain. They can think about moving their arm but those signals have nowhere to go. Using electrodes, we measure the signals and figure put how to move the prosthetic arm by bypassing the break,” McLoughlin says.
 
The development of the mechanical prosthetic limb grew out of the Revolutionizing Prosthetics program, a federal defense initiative that began in 2006 and has a year left to go before the project ends. The program's goal is to expand prosthetic arm options for the military's "wounded warriors."  The U.S. Department of Defense has been funding the program for a total of about $100 million so far. The brain/computer interface is the final phase of the program and, McLoughlin says, data about its research has not yet been published.
 
APL’s research partners in the program are the University of Pittsburgh Medical Center and School of Medicine, California Institute of Technology, University of Chicago, University of Utah and HDT Engineering Technologies, a private company in Ohio. 
 
The APL-led team of researchers have developed a modular prosthetic limb whose arm and hand are controlled by surface electrodes, in the case of amputees, and by a brain/computer interface, for spinal cord patients.

For spinal cord patients, physicians at the University of Pittsburgh will implant micro-electrodes in the brain of a paralyzed patient to record neural signals that control arm movement and to determine if the prosthetic arm can be controlled by the user’s thoughts.

The electrodes are inserted in the cortex of the brain. The prosthetic arm is mounted on a pedestal. The researchers developed the brain/computer interface by enhancing chip technology and combined it with algorithms to, as McLoughlin put it, “listen to and interpret what the brain is saying it wants to do.”
 
Earlier this year, for the first time and in cooperation with the Uniformed Services University of the Health Sciences and Walter Reed Military Medical Center, a U.S. Army soldier who lost both legs and his left arm to a roadside bomb in Afghanistan demonstrated the use of the prosthetic limb.

The prosthetic limb was featured in the May cover story of Popular Mechanics magazine, which called it a "smart bionic limb" and its direct neural control "the endgame of bionics."
 
 
Source: Michael McLoughlin, Johns Hopkins University Applied Physics Laboratory
Writer: Barbara Pash
 
 
 
 

Baltimore BioWorks is in the process of applying for state certification as a Minority Business Enterprise that would allow the life sciences manufacturing and training firm to bid on state contracts that set aside a slice of business for minority- and women-owned companies.

John Powers, president, says the company will bid on contracts for manufacturing and distribution at health-related agencies and systems like the Maryland Department of Health and Mental Hygiene and the University of Maryland Medical System.

The company expects to sign a lease for a 14,000-square foot manufacturing and distribution facility at 1100 Wicomico St., Baltimore City next month, after which it will begin to make, sell and ship biomedical products and to offer toxicology testing services. Earlier this month, the life sciences company opened its headquarters in the University of Maryland BioPark, on its downtown campus, and located a few blocks from the distribution facility.

In addition to toxicology testing, BioWorks will manufacture its own line of common biomedical products and buy and sell other lines of supplies like latex gloves, says Powers, who co-founded the privately-owned company this year with Louise Dalton, at a cost of about $1 million, split between the founders and the Abell Foundation.

Besides state agencies, Powers expects BioWorks customers’ in the private sector to range from institutions like Johns Hopkins Medical Institutions to biotechnology companies.

In addition to its own business ventures, BioWorks is providing training for workers in the biotech field. The company has a core staff of eight. Powers intends to add one full-time employee per month, or 12 employees per year, for ongoing, year-long vocational training. Trainees will be paid as they progress through a regimented program that covers all aspects of the field.

“It’s a paid position with benefits. It’s your first real job” in biotechnology, says Powers. “You can put it on your resume.”

Training positions are open to all qualified applicants although Powers is working in particular with the Baltimore City Community College Life Science Institute, which has an office at the UM BioPark. There will be an applicant review process, and graduates of the program will be given help finding a job.

However, the minority-focused training program is intended to be self-sustaining and depends on BioWorks’ sales. The company currently has $350,000 in annual sales but Powers says it is on track to reach the $1 million goal by the end of 2012 or early 2013.

The state Department of Transportation qualifies MBEs applicants; the Governor's Office of Minority Affairs administers the MBE requirements. The current goal is for about 25 percent of contracts in qualifying state agencies go to MBE companies.
 
Source: John Powers, Baltimore BioWorks
Writer: Barbara Pash